This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
What’s going on with CRISPR Therapeutics (NASDAQ: CRSP)? The company’s shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn’t recovered: The stock is down 23% year to date.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1178859368-4fa9eb73098c436a9b6ce77b0bb99472.jpg "Death Benefits in a Variable Annuity")
:max_bytes(150000):strip_icc():format(jpeg)/INV_SP500Gainers_Losers_2023_GettyImages-1223455297-196b1bea36f64240a70a0ce37ba6d1bc.jpg "Best Times of the Day, Week, and Month to Trade Stocks")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-172751278-cd584128c8ac48bbb99887a942f07eed.jpg "Why the Prices of Sports Tickets Vary So Much")